Fulcrum Therapeutics (FULC) PT Lowered to $14 at Oppenheimer
Tweet
Share
E-mailGet Alerts FULC Hot Sheet
Price: $3.77 +1.89%
Rating Summary:
4 Buy, 7 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Rating Summary:
4 Buy, 7 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Join SI Premium – FREE
Oppenheimer analyst Matthew Biegler lowered the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $14.00 (from $16.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Incyte (INCY) PT Raised to $105 at Truist Securities
- Definium Therapeutics Inc (DFTX) PT Raised to $60 at Oppenheimer
- Regenxbio Inc. (RGNX) PT Raised to $32 at Baird
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
